CRISPR Therapeutics AG (CRSP) stock
CRSPNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$42.24−0.38 (-0.89%)
Close on Nov 13, 2026Market cap $4.08BP/E –Yield –
CRISPR Therapeutics enterprise value
Enterprise value is market cap plus debt, minus cash: the value of the whole business to all its investors.
CRISPR Therapeutics's enterprise value was $2.06B on Nov 11, 2026, against $3.10B a year earlier. Over the last 5 years it ranged from $1.01B to $5.05B, with a median of $2.48B.
Enterprise Value at the end of each year
| Period | Period end | Value | Change |
|---|---|---|---|
| 2026 | Nov 11, 2026 | $2.06B | -31.6% |
| 2025 | Dec 31, 2025 | $3.01B | +111.3% |
| 2024 | Dec 31, 2024 | $1.42B | -56.0% |
| 2023 | Dec 29, 2023 | $3.23B | +151.6% |
| 2022 | Dec 30, 2022 | $1.28B | -61.3% |
| 2021 | Dec 31, 2021 | $3.32B | -64.9% |
| 2020 | Dec 31, 2020 | $9.44B | +245.7% |
| 2019 | Dec 31, 2019 | $2.73B | +177.1% |
| 2018 | Dec 31, 2018 | $985.62M | +41.9% |
| 2017 | Dec 29, 2017 | $694.65M | – |
| 2016 | Dec 30, 2016 | -$121.13M | – |
See a number that looks wrong?